Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Pharmaceuticals has received approval from the FDA to market amoxicillin and clavulanate potassium for oral suspension in the treatment of children with inflammation of the ear.
Subscribe to our email newsletter
The Division of Bioequivalence has determined the Ranbaxy formulation to be bioequivalent and, therefore, therapeutically equivalent to Augmentin ES-600, which was developed by GlaxoSmithKline.
Amoxicillin and clavulanate potassium is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to S. pneumoniae, H. influenzae, or M. catarrhalis. Otitis media is an inflammation of the middle ear segment of the ear.
“This again demonstrates our depth and breadth of expertise and adds to our ever-expanding product portfolio, complimenting our commitment to bring affordable generic alternatives to the US healthcare system. This product will be available in April 2007,” said Jim Meehan, vice president of Sales and Marketing for Ranbaxy Pharmaceuticals.